Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 66.93%-84.56K | -101.74K | 4.08%-69.5K | -513.36%-1.06M | -852.25%-729.03K | -312.56%-255.74K | 0 | 35.90%-72.46K | 77.34%-172.37K | 30.31%-76.56K |
| Net income from continuing operations | 125.10%96.98K | ---49.74K | 54.39%-131.19K | -289.80%-828.71K | -155.16%-154.68K | -497.19%-386.42K | --0 | -430.04%-287.61K | 151.84%436.62K | 297.54%280.42K |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---497K | ---297K |
| Unrealized gains and losses of investment securities | -375.00%-165K | ---72.5K | -77.38%47.5K | 376.42%340K | 204.48%70K | 400.00%60K | --0 | --210K | ---123K | ---67K |
| Remuneration paid in stock | ---- | ---- | ---- | 653.34%136.19K | --0 | --136.19K | --0 | --0 | -92.48%18.08K | --0 |
| Other non cashItems | ---15 | ---- | ---- | -6,928.06%-682.81K | ---554.42K | ---- | ---- | ---- | -24.24%10K | --0 |
| Change In working capital | -126.28%-16.53K | --25.53K | 175.50%14.19K | -28.35%-21.9K | -1,381.66%-89.93K | 6,046.92%62.88K | --0 | 133.12%5.15K | 90.10%-17.06K | 337.47%7.02K |
| -Change in receivables | 112.13%7.98K | --12.94K | 24,276.52%64.35K | -7,304.24%-74.78K | -236.65%-9.31K | -1,203.10%-65.73K | --0 | 102.80%264 | -98.93%1.04K | 341.00%6.81K |
| -Change in payables and accrued expense | -119.05%-24.5K | --12.59K | -1,126.46%-50.16K | 392.14%52.88K | -39,621.57%-80.62K | 2,705.69%128.62K | --0 | 179.85%4.89K | 93.27%-18.1K | -95.40%204 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 66.93%-84.56K | ---101.74K | 4.08%-69.5K | -513.36%-1.06M | -852.25%-729.03K | -312.56%-255.74K | --0 | 35.90%-72.46K | 77.34%-172.37K | 30.31%-76.56K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | ||||||||||
| Cash from discontinued investing activities | ||||||||||
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 730.55K | 0 | 0 | 0 | ||||||
| Net other financing activities | ---- | ---- | ---- | --730.55K | --0 | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | ---- | ---- | ---- | --730.55K | --0 | ---- | ---- | ---- | --0 | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -45.07%518.5K | -34.29%620.25K | -32.14%689.75K | -14.50%1.02M | 29.81%1.42M | -2.95%943.97K | -12.25%943.97K | -14.50%1.02M | -39.02%1.19M | -15.84%1.09M |
| Current changes in cash | -117.81%-84.56K | ---101.74K | 4.08%-69.5K | -89.53%-326.68K | -852.25%-729.03K | 294.66%474.81K | --0 | 35.90%-72.46K | 77.34%-172.37K | 30.31%-76.56K |
| End cash Position | -69.41%433.94K | -45.07%518.5K | -34.29%620.25K | -32.14%689.75K | -32.14%689.75K | 29.81%1.42M | -2.95%943.97K | -12.25%943.97K | -14.50%1.02M | -14.50%1.02M |
| Free cash from | 66.93%-84.56K | ---101.74K | 4.08%-69.5K | -513.36%-1.06M | -852.25%-729.03K | -312.56%-255.74K | --0 | 35.90%-72.46K | 77.34%-172.37K | 30.31%-76.56K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.